2024
Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).
Taylor M, Reddy S, Ashok Kumar P, Hariri D, Sokol E, Sivakumar S, Quintanilha J, Pavlick D, Levy M, Ross J, Lustberg M. Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2024, 42: 1092-1092. DOI: 10.1200/jco.2024.42.16_suppl.1092.Peer-Reviewed Original ResearchTriple negative breast cancerComprehensive genomic profilingGenomic alterationsHER2 statusHER2 2Triple negative breast cancer groupGA frequencyReview of pathology specimensHER2 IHC expressionHER2-low statusHER2-low tumorsLack of clinical dataPD-L1 expressionTumor mutational burdenHER2 IHC scoreHER2 2+Negative breast cancerEvaluate genomic alterationsMann-Whitney U testPotential treatment optionStatistically significant differenceHER2 subgroupsPD-L1Immunotherapy biomarkersChi-square test
2023
Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study
Blansky D, Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study. Breast Cancer Research And Treatment 2023, 204: 181-185. PMID: 37999916, DOI: 10.1007/s10549-023-07179-5.Peer-Reviewed Original ResearchComprehensive genomic profilingBreast cancerYoung womenGenomic alterationsAdvanced breast cancerPD-L1 expressionTargetable genomic alterationsWorse clinical outcomesTime of diagnosisTumor mutational burdenCross-sectional studyBreast cancer casesFoundation MedicineClinical outcomesPIK3CA mutationsCancer casesEstrogen receptorMutational burdenOlder womenConclusionOur findingsTotal casesBreast tumorsTumor tissueBRCA1 mutationsMicrosatellite instabilityMetastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.
Fanucci K, Lustberg M, Fischbach N, Pelletier M, Sivapiragasam A, Ashok Kumar P, Kallem M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study. Journal Of Clinical Oncology 2023, 41: 1036-1036. DOI: 10.1200/jco.2023.41.16_suppl.1036.Peer-Reviewed Original ResearchMetastatic breast cancerLobular histologyBreast cancerHER2 IHCGenomic alterationsComprehensive genomic profiling studyPD-L1 gene amplificationImmune checkpoint inhibitor treatmentMicrosatellite instabilityAxillary LN metastasisMetastatic site biopsySubset of ptsStage IV diseaseCheckpoint inhibitor treatmentPD-L1 expressionTumor mutational burdenMutations/MbMSI-high statusHER2 IHC resultsGenomic profiling studiesSite biopsiesSP142 assayLN metastasisMetastatic diseaseHigh TMBThe genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.
Lustberg M, Kaneva K, Teslow E, Mauer E, Federman N, Eisfeld A. The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing. Journal Of Clinical Oncology 2023, 41: e15091-e15091. DOI: 10.1200/jco.2023.41.16_suppl.e15091.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor mutational burdenCancer patientsAYA patientsMicrosatellite instabilityBreast cancerNext-generation sequencingYoung adult cancer patientsYoung adult malignancyColorectal cancer patientsAdult cancer patientsHER2- breast cancerOlder adult patientsAYA cancer patientsSoft tissue sarcomasCentral nervous systemHigh-grade gliomasLow-grade gliomasPathogenic single nucleotide variantsAYA cancerSingle nucleotide variantsAdult patientsGastrointestinal malignanciesNTRK fusionsAML subgroups
2022
Targetable genomic mutations in young women with advanced breast cancer.
Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Targetable genomic mutations in young women with advanced breast cancer. Journal Of Clinical Oncology 2022, 40: 1027-1027. DOI: 10.1200/jco.2022.40.16_suppl.1027.Peer-Reviewed Original ResearchComprehensive genomic profilingTumor mutational burdenAdvanced breast cancerPD-L1 expressionBreast cancerYoung womenImmune therapyPIK3CA mutationsGenomic alterationsTumor cell PD-L1 expressionClasses of GAsRB1 mutationsDisease-free survivalActionable genomic alterationsDifferent mutational profilesPARP inhibitor useImmunotherapy optionsInhibitor useFoundation MedicineLymph nodesWorse prognosisBRCA2 mutationsEstrogen receptorMutational burdenOlder women